Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Author:
Steve Schneible
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President...
Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR...
The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR,...
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents...
Researchers are building AI agents to assess how patients could respond to therapy and aid doctors in making cancer...
A few AACR Runners for Research shared their thoughts as they prepare to pound some pavement and raise money...
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond...
What are fusion proteins? Learn more about how improperly combined genes and their protein products can lead to cancer.